HCA Healthcare 10-Qquarter ended 2026-09-30

Executive Summary

HCA Healthcare provides hospital and outpatient care to patients, earning revenue from commercial insurers, Medicare, Medicaid and patients themselves. It is investing in existing facilities and nonhospital services while pursuing efficiency initiatives to withstand reimbursement changes and cost pressure. Q3 revenue grew 3.6%, but net income attributable to HCA fell 3.9% as higher nonlabor costs outweighed labor and supply efficiencies. Growing patient volumes support expansion, but rising uninsured admissions and uncertain Medicaid funding threaten the economics; share repurchases, rather than earnings growth, drove higher EPS.

What's Happening in the Business

Patient demand strengthened unevenly. Equivalent admissions, which combine inpatient and outpatient activity, increased 2.8%, and emergency visits rose 5.3%. However, inpatient surgeries fell 1.3% and outpatient surgeries declined 4.2%. Revenue per equivalent admission increased just 0.7%, making volume—not higher revenue per patient—the principal Q3 growth driver.

Coverage changes are making that growth harder to monetize. Uninsured admissions increased 27%, which management linked to expired enhanced Exchange premium tax credits, administrative reforms and fewer Medicaid conversions. Estimated uncompensated-care costs reached $1.48B, up 24%. Meanwhile, state-directed and supplemental payments, primarily in Florida, supported year-to-date Medicaid revenue, making government funding both a growth driver and a policy exposure.

HCA continues expanding its care network around 182 U.S. hospitals, seven hospitals in England and freestanding surgery and endoscopy centers. Nine-month acquisitions of nonhospital healthcare entities cost $942M, versus $361M spent on nonhospital entities and two hospitals a year earlier. Management plans FY2026 capital expenditures of $5.0B–$5.5B, excluding acquisitions; projects under construction require another $8.6B over five years. These investments expand capacity but also increase depreciation and funding needs.

Key Financial Highlights

• Medicaid contribution: 9M revenue of $6.00B, up 36%, supplied 51% of consolidated revenue growth, reflecting state-directed and supplemental programs primarily covering the preceding program year.
• Cost balance: Q3 salaries and supplies per equivalent admission fell 0.2% and 1.4%, respectively, but other operating expenses rose 9.3% to $4.55B because of inflation and other cost pressures.
• Segment profitability: National Group supplied the improvement in combined adjusted segment EBITDA; Atlantic and American generated less despite higher revenue. Segment EBITDA excludes expenses borne in consolidated earnings, including Q3 depreciation of $954M and interest of $607M, up 7.3% and 8.2%, respectively.
• Cash-flow bridge: Against broadly flat nine-month attributable earnings, OCF reflected $1.19B more income taxes paid, largely following a prior-year payment deferral, and $472M of unfavorable working-capital changes. After capital expenditures, FCF fell 25% to $5.10B.
• Capital returns: Nine-month repurchases were $6.61B vs $7.51B; dividends were $519M vs $517M. Shares outstanding fell 6.1% since year-end, while commercial paper increased to $5.73B from $2.21B.

Risk Assessment

• Coverage and reimbursement: Rising uninsured admissions increase uncompensated care, while federal restrictions on provider taxes and supplemental Medicaid payments could weaken funding that materially supported growth.
• Geographic concentration: Texas and Florida generated 51% of Q3 revenue and 73% of uninsured admissions, concentrating exposure to state coverage and reimbursement decisions.
• Funding flexibility: Current borrowings and debt due within one year reached $8.09B; credit-facility availability after commercial-paper reservations fell to $1.71B by 10/26/2026, increasing reliance on continued cash generation and refinancing access.

This 10-Q lists no risk factors of its own and refers to the annual report. The risks above come from the rest of this filing. Full list: the company's 10-Ks on SEC.

What to Watch

• Coverage economics: Uninsured admissions rose 27%; stabilization alongside stronger revenue per equivalent admission would support profitable volume growth, while further increases would deepen uncompensated-care pressure.
• Medicaid support: Nine-month Medicaid revenue reached $6.00B. Later filings will show whether supplemental payments sustain reimbursement or policy restrictions erode this growth source.
• Capacity utilization: Investment is expanding capacity while surgery volumes decline. Recovery in surgeries would support utilization; persistent declines would make added depreciation harder to absorb.
• Capital allocation: FCF trails repurchases alone. Stronger cash generation or moderated distributions would reduce borrowing pressure; continued funding gaps would increase refinancing dependence.